Neuropathic Pain Market By Drug class, By Indication, By Distribution channel : Global Opportunity Analysis and Industry Forecast, 2022-2032

Description

List of Tables

According to a new report published by Allied Market Research, titled, "Neuropathic Pain Market," The neuropathic pain market was valued at $7.7 billion in 2022, and is estimated to reach $13.3 billion by 2032, growing at a CAGR of 5.6% from 2022 to 2032. The neuropathic pain market is segmented on the basis of drug class, indication, distribution channel, and region.

Key Benefits For Stakeholders

This report provides a quantitative analysis of the market segments, current trends, estimations, and dynamics of the neuropathic pain market analysis from 2022 to 2032 to identify the prevailing neuropathic pain market opportunities.
The market research is offered along with information related to key drivers, restraints, and opportunities.
Porter's five forces analysis highlights the potency of buyers and suppliers to enable stakeholders make profit-oriented business decisions and strengthen their supplier-buyer network.
In-depth analysis of the neuropathic pain market segmentation assists to determine the prevailing market opportunities.
Major countries in each region are mapped according to their revenue contribution to the global market.
Market player positioning facilitates benchmarking and provides a clear understanding of the present position of the market players.
The report includes the analysis of the regional as well as global neuropathic pain market trends, key players, market segments, application areas, and market growth strategies.

Additional benefits you will get with this purchase are:

Quarterly Update and* (only available with a corporate license, on listed price)
5 additional Company Profile of client Choice pre- or Post-purchase, as a free update.
Free Upcoming Version on the Purchase of Five and Enterprise User License.
16 analyst hours of support* (post-purchase, if you find additional data requirements upon review of the report, you may receive support amounting to 16 analyst hours to solve questions, and post-sale queries)
15% Free Customization* (in case the scope or segment of the report does not match your requirements, 15% is equivalent to 3 working days of free work, applicable once)
Free data Pack on the Five and Enterprise User License. (Excel version of the report)
Free Updated report if the report is 6-12 months old or older.
24-hour priority response*
Free Industry updates and white papers.
Possible Customization with this report (with additional cost and timeline, please talk to the sales executive to know more)
Go To Market Strategy
Market share analysis of players by products/segments
New Product Development/ Product Matrix of Key Players
Additional company profiles with specific to client's interest
Additional country or region analysis- market size and forecast
Average Selling Price Analysis / Price Point Analysis
Brands Share Analysis
Expanded list for Company Profiles
Historic market data
SWOT Analysis

Key Market Segments

By Drug class

Antidepressants
- Type
- Tricyclic Antidepressants
- Serotonin-Noradrenaline Reuptake Inhibitors (SNRI)
Anticonvulsant
Opioids
Capsaicin
Others

By Indication

Diabetic Neuropathy
Spinal Stenosis
Chemotherapy-Induced Peripheral Neuropathy
Others

By Distribution channel

Hospital Pharmacies
Drugs Stores and Retail Pharmacies
Online Pharmacies

By Region

North America
- U.S.
- Canada
- Mexico
Europe
- Germany
- France
- UK
- Italy
- Spain
- Rest of Europe
Asia-Pacific
- Japan
- China
- Australia
- India
- South Korea
- Rest of Asia-Pacific
LAMEA
- Brazil
- Saudi Arabia
- South Africa
- Rest of LAMEA

Key Market Players:

Pfizer Inc.
Teva Pharmaceuticals
Novartis AG
Eli Lilly and Company.
Mallinckrodt Pharmaceuticals
Collegium Pharmaceutical Inc
Sun Pharmaceutical Industries Ltd.
Abbott Laboratories
Glenmark Pharmaceuticals Limited
Grunenthal GmbH.

Product Code: A05082

CHAPTER 1: INTRODUCTION

1.1. Report description
1.2. Key market segments
1.3. Key benefits to the stakeholders
1.4. Research methodology
- 1.4.1. Primary research
- 1.4.2. Secondary research
- 1.4.3. Analyst tools and models

CHAPTER 2: EXECUTIVE SUMMARY

2.1. CXO Perspective

CHAPTER 3: MARKET OVERVIEW

3.1. Market definition and scope
3.2. Key findings
- 3.2.1. Top impacting factors
- 3.2.2. Top investment pockets
3.3. Porter's five forces analysis
- 3.3.1. Low bargaining power of suppliers
- 3.3.2. Low threat of new entrants
- 3.3.3. Low threat of substitutes
- 3.3.4. Low intensity of rivalry
- 3.3.5. Low bargaining power of buyers
3.4. Market dynamics
- 3.4.1. Drivers
  - 3.4.1.1. Rise in cases of neuropathic pain
  - 3.4.1.2. Rise in prevalence of chronic diseases
  - 3.4.1.3. Rise in geriatric population
- 3.4.2. Restraints
  - 3.4.2.1. Side effects of neuropathic pain medicine
- 3.4.3. Opportunities
  - 3.4.3.1. Rise in number of drugs in pipeline

CHAPTER 4: NEUROPATHIC PAIN MARKET, BY DRUG CLASS

4.1. Overview
- 4.1.1. Market size and forecast
4.2. Antidepressants
- 4.2.1. Key market trends, growth factors and opportunities
- 4.2.2. Market size and forecast, by region
- 4.2.3. Market share analysis by country
- 4.2.4. Antidepressants Neuropathic Pain Market by Type
4.3. Anticonvulsant
- 4.3.1. Key market trends, growth factors and opportunities
- 4.3.2. Market size and forecast, by region
- 4.3.3. Market share analysis by country
4.4. Opioids
- 4.4.1. Key market trends, growth factors and opportunities
- 4.4.2. Market size and forecast, by region
- 4.4.3. Market share analysis by country
4.5. Capsaicin
- 4.5.1. Key market trends, growth factors and opportunities
- 4.5.2. Market size and forecast, by region
- 4.5.3. Market share analysis by country
4.6. Others
- 4.6.1. Key market trends, growth factors and opportunities
- 4.6.2. Market size and forecast, by region
- 4.6.3. Market share analysis by country

CHAPTER 5: NEUROPATHIC PAIN MARKET, BY INDICATION

5.1. Overview
- 5.1.1. Market size and forecast
5.2. Diabetic Neuropathy
- 5.2.1. Key market trends, growth factors and opportunities
- 5.2.2. Market size and forecast, by region
- 5.2.3. Market share analysis by country
5.3. Spinal Stenosis
- 5.3.1. Key market trends, growth factors and opportunities
- 5.3.2. Market size and forecast, by region
- 5.3.3. Market share analysis by country
5.4. Chemotherapy-Induced Peripheral Neuropathy
- 5.4.1. Key market trends, growth factors and opportunities
- 5.4.2. Market size and forecast, by region
- 5.4.3. Market share analysis by country
5.5. Others
- 5.5.1. Key market trends, growth factors and opportunities
- 5.5.2. Market size and forecast, by region
- 5.5.3. Market share analysis by country

CHAPTER 6: NEUROPATHIC PAIN MARKET, BY DISTRIBUTION CHANNEL

6.1. Overview
- 6.1.1. Market size and forecast
6.2. Hospital Pharmacies
- 6.2.1. Key market trends, growth factors and opportunities
- 6.2.2. Market size and forecast, by region
- 6.2.3. Market share analysis by country
6.3. Drugs Stores and Retail Pharmacies
- 6.3.1. Key market trends, growth factors and opportunities
- 6.3.2. Market size and forecast, by region
- 6.3.3. Market share analysis by country
6.4. Online Pharmacies
- 6.4.1. Key market trends, growth factors and opportunities
- 6.4.2. Market size and forecast, by region
- 6.4.3. Market share analysis by country

CHAPTER 7: NEUROPATHIC PAIN MARKET, BY REGION

7.1. Overview
- 7.1.1. Market size and forecast By Region
7.2. North America
- 7.2.1. Key market trends, growth factors and opportunities
- 7.2.2. Market size and forecast, by Drug class
- 7.2.3. Market size and forecast, by Indication
- 7.2.4. Market size and forecast, by Distribution channel
- 7.2.5. Market size and forecast, by country
  - 7.2.5.1. U.S.
  - 7.2.5.1.1. Market size and forecast, by Drug class
  - 7.2.5.1.2. Market size and forecast, by Indication
  - 7.2.5.1.3. Market size and forecast, by Distribution channel
  - 7.2.5.2. Canada
  - 7.2.5.2.1. Market size and forecast, by Drug class
  - 7.2.5.2.2. Market size and forecast, by Indication
  - 7.2.5.2.3. Market size and forecast, by Distribution channel
  - 7.2.5.3. Mexico
  - 7.2.5.3.1. Market size and forecast, by Drug class
  - 7.2.5.3.2. Market size and forecast, by Indication
  - 7.2.5.3.3. Market size and forecast, by Distribution channel
7.3. Europe
- 7.3.1. Key market trends, growth factors and opportunities
- 7.3.2. Market size and forecast, by Drug class
- 7.3.3. Market size and forecast, by Indication
- 7.3.4. Market size and forecast, by Distribution channel
- 7.3.5. Market size and forecast, by country
  - 7.3.5.1. Germany
  - 7.3.5.1.1. Market size and forecast, by Drug class
  - 7.3.5.1.2. Market size and forecast, by Indication
  - 7.3.5.1.3. Market size and forecast, by Distribution channel
  - 7.3.5.2. France
  - 7.3.5.2.1. Market size and forecast, by Drug class
  - 7.3.5.2.2. Market size and forecast, by Indication
  - 7.3.5.2.3. Market size and forecast, by Distribution channel
  - 7.3.5.3. UK
  - 7.3.5.3.1. Market size and forecast, by Drug class
  - 7.3.5.3.2. Market size and forecast, by Indication
  - 7.3.5.3.3. Market size and forecast, by Distribution channel
  - 7.3.5.4. Italy
  - 7.3.5.4.1. Market size and forecast, by Drug class
  - 7.3.5.4.2. Market size and forecast, by Indication
  - 7.3.5.4.3. Market size and forecast, by Distribution channel
  - 7.3.5.5. Spain
  - 7.3.5.5.1. Market size and forecast, by Drug class
  - 7.3.5.5.2. Market size and forecast, by Indication
  - 7.3.5.5.3. Market size and forecast, by Distribution channel
  - 7.3.5.6. Rest of Europe
  - 7.3.5.6.1. Market size and forecast, by Drug class
  - 7.3.5.6.2. Market size and forecast, by Indication
  - 7.3.5.6.3. Market size and forecast, by Distribution channel
7.4. Asia-Pacific
- 7.4.1. Key market trends, growth factors and opportunities
- 7.4.2. Market size and forecast, by Drug class
- 7.4.3. Market size and forecast, by Indication
- 7.4.4. Market size and forecast, by Distribution channel
- 7.4.5. Market size and forecast, by country
  - 7.4.5.1. Japan
  - 7.4.5.1.1. Market size and forecast, by Drug class
  - 7.4.5.1.2. Market size and forecast, by Indication
  - 7.4.5.1.3. Market size and forecast, by Distribution channel
  - 7.4.5.2. China
  - 7.4.5.2.1. Market size and forecast, by Drug class
  - 7.4.5.2.2. Market size and forecast, by Indication
  - 7.4.5.2.3. Market size and forecast, by Distribution channel
  - 7.4.5.3. Australia
  - 7.4.5.3.1. Market size and forecast, by Drug class
  - 7.4.5.3.2. Market size and forecast, by Indication
  - 7.4.5.3.3. Market size and forecast, by Distribution channel
  - 7.4.5.4. India
  - 7.4.5.4.1. Market size and forecast, by Drug class
  - 7.4.5.4.2. Market size and forecast, by Indication
  - 7.4.5.4.3. Market size and forecast, by Distribution channel
  - 7.4.5.5. South Korea
  - 7.4.5.5.1. Market size and forecast, by Drug class
  - 7.4.5.5.2. Market size and forecast, by Indication
  - 7.4.5.5.3. Market size and forecast, by Distribution channel
  - 7.4.5.6. Rest of Asia-Pacific
  - 7.4.5.6.1. Market size and forecast, by Drug class
  - 7.4.5.6.2. Market size and forecast, by Indication
  - 7.4.5.6.3. Market size and forecast, by Distribution channel
7.5. LAMEA
- 7.5.1. Key market trends, growth factors and opportunities
- 7.5.2. Market size and forecast, by Drug class
- 7.5.3. Market size and forecast, by Indication
- 7.5.4. Market size and forecast, by Distribution channel
- 7.5.5. Market size and forecast, by country
  - 7.5.5.1. Brazil
  - 7.5.5.1.1. Market size and forecast, by Drug class
  - 7.5.5.1.2. Market size and forecast, by Indication
  - 7.5.5.1.3. Market size and forecast, by Distribution channel
  - 7.5.5.2. Saudi Arabia
  - 7.5.5.2.1. Market size and forecast, by Drug class
  - 7.5.5.2.2. Market size and forecast, by Indication
  - 7.5.5.2.3. Market size and forecast, by Distribution channel
  - 7.5.5.3. South Africa
  - 7.5.5.3.1. Market size and forecast, by Drug class
  - 7.5.5.3.2. Market size and forecast, by Indication
  - 7.5.5.3.3. Market size and forecast, by Distribution channel
  - 7.5.5.4. Rest of LAMEA
  - 7.5.5.4.1. Market size and forecast, by Drug class
  - 7.5.5.4.2. Market size and forecast, by Indication
  - 7.5.5.4.3. Market size and forecast, by Distribution channel

CHAPTER 8: COMPETITIVE LANDSCAPE

8.1. Introduction
8.2. Top winning strategies
8.3. Product mapping of top 10 player
8.4. Competitive dashboard
8.5. Competitive heatmap
8.6. Top player positioning, 2022

CHAPTER 9: COMPANY PROFILES

9.1. Pfizer Inc.
- 9.1.1. Company overview
- 9.1.2. Key executives
- 9.1.3. Company snapshot
- 9.1.4. Operating business segments
- 9.1.5. Product portfolio
- 9.1.6. Business performance
9.2. Teva Pharmaceuticals
- 9.2.1. Company overview
- 9.2.2. Key executives
- 9.2.3. Company snapshot
- 9.2.4. Operating business segments
- 9.2.5. Product portfolio
- 9.2.6. Business performance
9.3. Glenmark Pharmaceuticals Limited
- 9.3.1. Company overview
- 9.3.2. Key executives
- 9.3.3. Company snapshot
- 9.3.4. Operating business segments
- 9.3.5. Product portfolio
- 9.3.6. Business performance
9.4. Novartis AG
- 9.4.1. Company overview
- 9.4.2. Key executives
- 9.4.3. Company snapshot
- 9.4.4. Operating business segments
- 9.4.5. Product portfolio
- 9.4.6. Business performance
9.5. Mallinckrodt Pharmaceuticals
- 9.5.1. Company overview
- 9.5.2. Key executives
- 9.5.3. Company snapshot
- 9.5.4. Operating business segments
- 9.5.5. Product portfolio
- 9.5.6. Business performance
9.6. Eli Lilly and Company.
- 9.6.1. Company overview
- 9.6.2. Key executives
- 9.6.3. Company snapshot
- 9.6.4. Operating business segments
- 9.6.5. Product portfolio
- 9.6.6. Business performance
- 9.6.7. Key strategic moves and developments
9.7. Grunenthal GmbH.
- 9.7.1. Company overview
- 9.7.2. Key executives
- 9.7.3. Company snapshot
- 9.7.4. Operating business segments
- 9.7.5. Product portfolio
- 9.7.6. Business performance
- 9.7.7. Key strategic moves and developments
9.8. Collegium Pharmaceutical Inc
- 9.8.1. Company overview
- 9.8.2. Key executives
- 9.8.3. Company snapshot
- 9.8.4. Operating business segments
- 9.8.5. Product portfolio
- 9.8.6. Business performance
- 9.8.7. Key strategic moves and developments
9.9. Sun Pharmaceutical Industries Ltd.
- 9.9.1. Company overview
- 9.9.2. Key executives
- 9.9.3. Company snapshot
- 9.9.4. Operating business segments
- 9.9.5. Product portfolio
- 9.9.6. Business performance
9.10. Abbott Laboratories
- 9.10.1. Company overview
- 9.10.2. Key executives
- 9.10.3. Company snapshot
- 9.10.4. Operating business segments
- 9.10.5. Product portfolio
- 9.10.6. Business performance